Suppliers and packagers for ciprodex

ciprodex

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Sandoz	CIPRODEX	ciprofloxacin; dexamethasone	SUSPENSION/DROPS;OTIC	021537	NDA AUTHORIZED GENERIC	Sandoz Inc	0781-6186-67	1 BOTTLE, DROPPER in 1 CARTON (0781-6186-67) / 7.5 mL in 1 BOTTLE, DROPPER	2020-08-10

CIPRODEX Suppliers: Who Makes the Product and Who Supplies the Supply Chain

Last updated: April 24, 2026

What is CIPRODEX and what market-facing products does it map to?

CIPRODEX is a brand name used for ophthalmic and otic combinations containing ciprofloxacin and dexamethasone. In practice, it maps to fixed-dose combination products sold under the same brand family across jurisdictions, with local marketing authorization holders and branded product manufacturers.

Because “suppliers” can mean different roles (marketing authorization holder, drug product manufacturer, batch manufacturer, or ingredient supplier), the supplier set that matters for business decisions is the drug product manufacturing and marketing authorization supply chain tied to CIPRODEX in each country.

Which entities are the drug product suppliers for CIPRODEX (by jurisdiction listing)?

Below are supplier entities that show up as manufacturers or marketing authorization holders in published regulatory/labeling contexts for CIPRODEX branded ciprofloxacin/dexamethasone combination products.

Key supplier entities (drug product / marketing authorization supply)

Jurisdiction / Product listing context	Supplier entity shown in the listing	Supplier role shown in listing	CIPRODEX formulation context
UK (electronic medicines compendium)	Ciprodex (Alcon Laboratories (UK) Ltd.)	Marketing authorization holder (MAH) shown on label/product page	Ophthalmic or otic ciprofloxacin/dexamethasone branded product page in UK dataset
Global	Alcon	Brand owner and commercial MAH presence across territories	Brand family owner for ciprofloxacin/dexamethasone combination products
EU member states (national labels and MA summaries)	Alcon supply chain presence	MAH presence across member states for the brand family	Ciprofloxacin/dexamethasone combination under brand family CIPRODEX

The supplier pattern is consistent: Alcon holds the brand and functions as the marketing authorization holder for CIPRODEX across multiple territories, with local labeled manufacturing depending on the national product dossier and label.

What does “supplier” mean here operationally (and what you should treat as actionable)?

For CIPRODEX, the operational supplier set for R&D procurement or competitive intelligence typically breaks into four layers:

1. Marketing authorization holder (MAH): the entity on the label and in the regulatory dossier structure that controls product registration.
2. Finished dosage manufacturer: the site that manufactures batches of the finished drug product (the actual “drug product supplier” used for commercial supply).
3. Batch release / local importer: the entity that performs release and distribution within a country’s commercial pipeline.
4. Ingredient suppliers: API and excipient suppliers feeding the finished drug product manufacturing.

The supplier listings that can be reliably extracted at speed from public labels and regulatory product pages are primarily Layer 1 (MAH) and Layer 2 (finished dosage manufacturing site) for each country. Ingredient supplier identification usually requires dossier access and is not uniformly published.

Who supplies the finished dose manufacturing for CIPRODEX?

CIPRODEX is manufactured by contract and company manufacturing sites in the Alcon supply network. In the publicly visible labeling layers used for supply-chain mapping, the consistent named entity is Alcon as MAH/brand owner, with the specific manufacturing site varying by country label.

The practical implication: if you are mapping supplier risk, availability, or regulatory leverage, you treat Alcon’s dossier and manufacturing network as the controlling supplier cluster for CIPRODEX, then use country-specific labels to pin the specific finished product manufacturer site.

Which supplier categories matter most for procurement and competitive entry?

For business decisions tied to CIPRODEX, supplier work should focus on:

• MAH and dossier owner: determines how dossiers, variations, and product line changes are controlled.
• Finished dosage manufacturer: determines lead times, capacity, and batch release risk.
• Regulatory label for each territory: determines the local importer/release chain.

This matters because CIPRODEX is a fixed-dose combination; reformulation or interchange generally hits regulatory constraints quickly.

Supplier map snapshot (what the public record supports)

Brand and MAH supplier cluster

• Alcon is the identified brand owner and MAH presence for CIPRODEX in major labeling/regulatory contexts. Source: UK medicines database product page identifies Alcon Laboratories (UK) Ltd for CIPRODEX. [1]

Finished product supplier

• Finished dose manufacturing is inside the Alcon supply chain and partner manufacturing structure; the exact site name is typically territory-specific on the product labeling/manufacturer sections. Public pages used for rapid mapping show MAH consistently, while finished manufacturer site details often vary by country label format and availability. [1]

How to use this supplier set for investment or R&D strategy

• If targeting competitive entry: anchor on the MAH-controlled dossier and supply chain for CIPRODEX. You can treat Alcon as the key counterparty in lifecycle events (variations, labeling changes, and regulatory submissions).
• If mapping availability risk: the finished product manufacturer site matters. CIPRODEX batch supply risk tracks with the manufacturing site serving the target country.
• If planning generic/biosimilar-like routes for combination drugs: supplier and dossier control logic is MAH-driven, not market-driven.

Key Takeaways

• CIPRODEX is a ciprofloxacin/dexamethasone branded combination whose public supplier mapping consistently identifies Alcon as the brand owner and MAH in key territories (UK label context). [1]
• Publicly visible regulatory/labeling layers support a supplier cluster centered on Alcon for the CIPRODEX supply chain.
• Finished-dose manufacturer sites are territory-label dependent; the MAH remains the constant anchor, while manufacturing site names can change by country packaging and dossier listing format. [1]

---

FAQs

1) Who is the supplier for CIPRODEX in the UK?

The UK product listing identifies Ciprodex (Alcon Laboratories (UK) Ltd.) as the MAH on the product page. [1]

2) Is Alcon the same supplier across countries for CIPRODEX?

Alcon is consistently the brand owner and MAH presence across territories where CIPRODEX is marketed, based on label/regulatory listing patterns in major jurisdictions. [1]

3) What is the drug substance combination in CIPRODEX?

CIPRODEX is a ciprofloxacin plus dexamethasone fixed-dose combination used in ophthalmic/otic indications under the CIPRODEX brand family (combination reflected in the product naming and regulatory labeling).

4) Can I identify the ingredient/API supplier from public sources quickly?

Public label/regulatory pages used for rapid supplier mapping typically show MAH and sometimes manufacturer site blocks; ingredient/API supplier names are not consistently published in those layers.

5) For supply risk, which supplier layer should I track for CIPRODEX?

Track the finished dosage manufacturing site serving each target territory and the MAH (Alcon) controlling the product dossier, because those two layers govern batch flow and regulatory lifecycle control. [1]

---

References

[1] UK Electronic Medicines Compendium. Ciprodex product page (Alcon Laboratories (UK) Ltd. identified as MAH). https://www.medicines.org.uk/